Theravance Biopharma Posts $5.9M Q2 Loss Amid Pending Zymeworks Acquisition
TBPH sits 53% above its 52-week low of $11.045 on elevated volume (4.3× avg).
Summary
Theravance Biopharma reported a Q2 net loss of $5.9 million, a significant improvement from the prior year's loss. This follows the June 29 announcement of a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash. The pending acquisition likely mutes the standalone earnings impact, but the reduced loss shows operational progress. The deal is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
At the time of this announcement, TBPH was trading at $16.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $877.5M. The 52-week trading range was $11.05 to $21.03. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.